| Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. | |
| | |
MedLine Citation:
|
PMID: 20033054 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification. Therefore, there is an increasing need for standardization of methodologies and harmonization of terminology. For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR- and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. The panel summarized the current state of MRD diagnostics in ALL and developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials. Finally, a common terminology for a standard description of MRD response and monitoring was established defining the terms 'complete MRD response', 'MRD persistence' and 'MRD reappearance'. The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols. |
| | |
Authors:
|
M Br?ggemann; A Schrauder; T Raff; H Pfeifer; M Dworzak; O G Ottmann; V Asnafi; A Baruchel; R Bassan; Y Benoit; A Biondi; H Cav?; H Dombret; A K Fielding; R Fo?; N G?kbuget; A H Goldstone; N Goulden; G Henze; D Hoelzer; G E Janka-Schaub; E A Macintyre; R Pieters; A Rambaldi; J-M Ribera; K Schmiegelow; O Spinelli; J Stary; A von Stackelberg; M Kneba; M Schrappe; J J M van Dongen; ; |
Related Documents
:
|
19836734 - Egg freezing, procreative liberty, and icsi: the double standards confronting elective ... 5296134 - The international standard for novobiocin. 4119514 - International standards and international reference preparations: amphotericin b, vanco... 14582724 - International radiation safety standards. 17780504 - Eastern europe: serbian university law causes turmoil. 10761144 - Coverage of indian leather patents in chemical abstracts |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review Date: 2009-12-24 |
Journal Detail:
|
Title: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K Volume: 24 ISSN: 1476-5551 ISO Abbreviation: Leukemia Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-03-10 Completed Date: 2010-03-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8704895 Medline TA: Leukemia Country: England |
Other Details:
|
Languages: eng Pagination: 521-35 Citation Subset: IM |
Affiliation:
|
Department of Hematology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. m.brueggemann@med2.uni-kiel.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Flow Cytometry Fusion Proteins, bcr-abl / genetics Gene Rearrangement Genes, Immunoglobulin Humans Neoplasm, Residual / diagnosis Polymerase Chain Reaction Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis*, therapy |
| Chemical | |
Reg. No./Substance:
|
0/Fusion Proteins, bcr-abl |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mobilization studies in complement-deficient mice reveal that optimal AMD3100 mobilization of hemato...
Next Document: CD3(+)/CD19(+)-depleted grafts in HLA-matched allogeneic peripheral blood stem cell transplantation ...